- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04367597
Evaluation of NMES Therapy for Pain Relief Associated With Knee Osteoarthritis
March 16, 2021 updated by: CyMedica Orthopedics, Inc
A Roll-over Study of CM-2019 Trial (A Randomized, Sham Controlled, Double-blind, Multi-center Study of Neuromuscular Electrical Stimulation (NMES) as an Adjunctive Therapy for Knee Pain Relief and Improving Functional Outcomes in Knee Osteoarthritis (OA) Patients)
A roll-over study of the current CM-2019 trial to assess the same preplanned outcomes of CM-2019 at 14 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This roll-over study is designed as a 14-week treatment continuation from CM-2019 (parent study), a randomized, sham controlled, double-blind, multi-center study trial to evaluate the efficacy of CyMedica Orthopedics e-vive™ system, a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES) as an adjunctive therapy for pain relief and accelerating functional recovery in patients with knee osteoarthritis.
This follow-up trial will include subjects who have been randomized into the CM-2019 trial.
Subjects will be enrolled into the appropriate treatment group based upon the treatment received in the parent study.
It is hypothesized that the continued use of CyMedica e-vive NMES may provide additional pain relief and improved knee function for an additional 14 weeks compared to sham.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- Noble Clinical Research
-
Tucson, Arizona, United States, 85712
- Tucson Orthopedic Institute
-
-
Texas
-
Houston, Texas, United States, 77061
- Synergy Group US LLC
-
Katy, Texas, United States, 77450
- Synergy Group US LLC
-
Missouri City, Texas, United States, 77459
- Synergy Group US LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject must provide a signed informed consent for CM-2019R. The subject will be provided with a copy of the signed Informed Consent upon signature.
- Currently enrolled in the parent trial CM-2019 or have successfully completed the parent trial within 21 days of enrollment in the roll-over trial.
- Willing and able to continue parent trial study treatment.
- Pregnancy test, if it has been >14 days since completion of the parent trial.
- Subject must continue to be willing to refrain from receiving knee intra-articular injections of steroids, knee intra-articular injections of hyaluronic acid, opioids, and analgesics (except for acetaminophen up to 3000 mg/day or an equivalent) for the duration of the study.
- Subject must continue to be willing to take acetaminophen (up to 3000 mg/day) or an equivalent as pain medication for the duration of the study.
- Subject must continue to be willing to stop taking any pain medications 24 hours prior any scheduled study visit.
- Subject must continue to be willing to stop receiving knee physical therapy of the target knee for the duration of the study.
- Subject must continue be willing to stop wearing any knee unloader brace of the target knee for the duration of the study.
- Subjects must be willing and able to comply with all study procedures for the duration of the clinical study
Exclusion Criteria:
- Subjects with a new diagnosis of inflammatory arthritis (knee rheumatoid arthritis, active gout, knee joint infection, Lyme disease, SLE, etc.) since parent trial enrollment.
- Subjects with a new diagnosis of severe neuropathy condition and under medication for treatment of the condition since parent trial enrollment.
- Subjects with a new diagnosis of fibromyalgia since parent trial enrollment.
- Subjects who have had an injury or an acute traumatic injury to the target knee since parent trial enrollment.
- Subject must NOT have had arthroscopy of the target knee since parent trial enrollment.
- Subjects who have had treatment of the target knee with intra-articular injections of steroids since parent trial enrollment. Subjects who have had intra-articular injections of hyaluronic acid since parent trial enrollment.
- Subjects who have a scheduled surgery on the target knee within the study period. (Subjects that are contemplating the surgery can be included.)
- Subjects who have used electrotherapy or acupuncture for OA of the target knee since parent trial enrollment year.
- Subjects who have had implanted electrical devices since parent trial enrollment (cardiac pacemakers, deep brain stimulators, implantable cardiac defibrillators).
- Subjects with a current new malignancy or who have received treatment for malignancy since parent trial enrollment, with the exception of resected basal cell carcinoma and squamous cell carcinoma of the skin.
- Subjects with a new skin breakdown or infection in the area where the study device will be placed (quadriceps of the target knee).
- Subjects with any newly reported chronic conditions (e.g., diabetes, hypertension, congestive heart failure, etc.) or that have not been well-controlled during the parent trial.
- Subjects who have any new litigation for worker's compensation.
- Subjects with any new condition, in the opinion of the Investigator that might interfere with the evaluation of the study objectives.
- Subjects who are pregnant.
- Subject who enrolled in any new clinical study from the last day of treatment in the parent trial that required the use of an investigational device, drug or biologic.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active NMES
|
A home-based NMES treatment applied by the subjects daily
|
Sham Comparator: Modified NMES sham
|
A home-based NMES treatment applied by the subjects daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knee pain
Time Frame: 14 weeks post intervention
|
Assessment of knee pain relief associated with knee osteoarthritis using VAS instrument scale
|
14 weeks post intervention
|
Knee pain and function
Time Frame: 14 weeks post intervention
|
Assessment of knee pain relief and function improvements associated with knee osteoarthritis using WOMAC survey
|
14 weeks post intervention
|
Knee pain and function
Time Frame: 14 weeks post intervention
|
Assessment of knee pain relief and function improvements associated with knee osteoarthritis using KOOS Jr. survey
|
14 weeks post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knee function
Time Frame: 14 weeks post intervention
|
Knee functional improvements including quadriceps strength tes
|
14 weeks post intervention
|
Knee function
Time Frame: 14 weeks post intervention
|
Knee functional improvements including Timed Up and Go test
|
14 weeks post intervention
|
Knee function
Time Frame: 14 weeks post intervention
|
Knee functional improvements including 3 Min walk test
|
14 weeks post intervention
|
Knee function
Time Frame: 14 weeks post intervention
|
Knee functional improvements including Repeated chair rise test
|
14 weeks post intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 20, 2020
Primary Completion (Actual)
August 20, 2020
Study Completion (Actual)
March 16, 2021
Study Registration Dates
First Submitted
April 23, 2020
First Submitted That Met QC Criteria
April 27, 2020
First Posted (Actual)
April 29, 2020
Study Record Updates
Last Update Posted (Actual)
March 18, 2021
Last Update Submitted That Met QC Criteria
March 16, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CM-2019R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Tianjin XinChen-Techfields Pharma Co., LTD.Completed
-
Eun Jung KimMinistry of Health & Welfare, Korea; Semyung UniversityUnknownOsteoarthritis KneeKorea, Republic of
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
Clinical Trials on Home-based Neuromuscular Electrical Stimulation (NMES) therapy
-
The Hospital for Sick ChildrenCompleted
-
Federal University of Health Science of Porto AlegreNot yet recruitingAnterior Cruciate Ligament Reconstruction | Anterior Cruciate Ligament Reconstruction RehabilitationBrazil
-
Oregon Health and Science UniversityCompletedIntensive Care (ICU) MyopathyUnited States
-
Research Institute for Complex Problems of Cardiovascular...UnknownHeart Failure | Sarcopenia | Peripheral Artery Disease | Exercise IntoleranceRussian Federation
-
Chang Gung Memorial HospitalCompleted
-
University of VermontRecruitingCommunity-acquired Pneumonia | COPD Exacerbation AcuteUnited States
-
Dr. Soetomo General HospitalCompletedChronic Heart FailureIndonesia
-
Maastricht University Medical CenterTerminatedImmobilization | Muscle Disuse AtrophyNetherlands
-
University of PittsburghKing Fahad Specialist Hospital Dammam; Saudi Arabian Cultural MissionCompleted
-
University of VermontCompletedKnee OsteoarthritisUnited States